Tetramethyluric acid
Based on 1 Customer Validation
Tetramethyluric acid (1,3,7,9-Tetramethyluric acid) is an orally active purine alkaloid in Coffea species and Camellia kucha. Tetramethyluric acid exhibits antiviral, and anti-inflammatory activity. Tetramethyluric acid can be used for the research of inflammation disease, and influenza virus infection.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 2309-49-1
- Formula: C9H12N4O3
- Molecular Weight:224.22
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
MAPK Compound Library
HY-L010
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Histone Modification Research Compound Library
HY-L024
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Neuroprotective Compound Library
HY-L070
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Food-Sourced Compound Library
HY-L094
-
Anti-Liver Cancer Compound Library
HY-L101
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Osteogenesis Compound Library
HY-L131
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Biological Activity
|
SIRT3 |
IL-6 |
IL-1β |
Tetramethyluric acid (50-100 μM) exhibits anti-influenza virus activity in MDCK cells, inhibiting NS1 protein expression[1].
Tetramethyluric acid (1.5×10-2 M) reduces 32P-labelled orthophosphate incorporation into DNA and RNA and increases ATP levels by 40% in excised Vicia faba root tips[2].
Tetramethyluric acid (2×10-2 M; 120 min) induces chromosomal aberrations in Vicia faba root tips[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tetramethyluric acid (20 mg/kg; i.g.) improves cardiac function in ovariectomized mice with myocardial infarction by activating SIRT3 and reducing myocardial fibrosis and apoptosis[1].
Tetramethyluric acid (8-32 mg/kg; p.o.; single dose) significantly inhibits Xylene-induced ear edema and λ-Carrageenan (HY-N9470)-induced hind paw edema[1].
Tetramethyluric acid (10-30 mg/kg; p.o.; daily; 7 days) reduces hepatic inflammation and liver damage in restraint-stressed mice[1].
Tetramethyluric acid (12.5-25.0 mg/kg; p.o.) attenuates FIA-induced rheumatoid arthritis in SD rats via the TGF-β/SMAD pathway[1].
Tetramethyluric acid (24-48 mg/kg; i.p.; single pre-treatment dose) significantly attenuates adenosine receptor agonist-induced motor depression in Long Evans rats via adenosergic and dopaminergic systems[1].
Tetramethyluric acid (5-15 mg/kg; p.o.) reverses restraint stress-induced learning and memory impairment in male Kunming mice[1].
Tetramethyluric acid (3-30 mg/kg; i.g.) produces antidepressant effects in male NIH mice by modulating monoamine neurotransmitters[1].
Tetramethyluric acid (10-20 mg/kg; p.o.) ameliorates HFD-induced NAFLD in C57BL/6 mice via the SIRT3/LCAD signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice intervertebral disc degeneration model[1]
-
Dosage:10 mg/kg
-
Administration:p.o.
-
Result:Stimulated the expression of collagen II, SIRT3, FOXO3a, and SOD2.
-
Animal Model:Estrogen-deficient mice[1]
-
Dosage:20 mg/kg
-
Administration:i.g.
-
Result:Activated SIRT3, repressed myocardial fibrosis and apoptosis, and improved cardiac function.
-
Animal Model:Mice with ear and hind paw edema induced by Xylene and λ-Carrageenan[1]
-
Dosage:8; 16; 32 mg/kg
-
Administration:p.o.; single dose
-
Result:Inhibited Xylene-induced ear edema with inhibition percentages of 10.1%, 12.9%, and 45.2% at 8, 16, and 32 mg/kg respectively.
Achieved maximal anti-edema effects at 2 hours post-induction of 14.1%, 16.6%, and 20.1% at 8, 16, and 32 mg/kg, respectively.
Inhibited λ-Carrageenan-induced hind paw edema in a dose-dependent manner.
-
Animal Model:Restraint-stressed mice[1]
-
Dosage:10; 20; 30 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Reduced hepatic mRNA levels of IL-6, IL-1β, TNF-α, and IFN-γ.
Decreased plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.
Reversed histologic liver damage.
-
Animal Model:Sprague-Dawley (SD) rats with rheumatoid arthritis induced by FIA[1]
-
Dosage:12.5; 25.0 mg/kg
-
Administration:p.o.
-
Result:Attenuated rheumatoid arthritis by suppressing IL-6 and activating TGF-β via the TGF-β/SMAD pathway.
Upregulated RNA and protein expression of SMAD3, p-ERK, and p-p38.
Downregulated nuclear factor-kB (NF-kB) and IL-6 expression.
-
Animal Model:Long Evans rats[1]
-
Dosage:24; 48 mg/kg
-
Administration:i.p.; single pre-treatment dose
-
Result:Significantly attenuated motor depression induced by adenosine receptor agonists, an effect reduced by D1R and D2R antagonists.
-
Animal Model:Male Kunming mice[1]
-
Dosage:5; 10; 15 mg/kg
-
Administration:p.o.
-
Result:Significantly reversed learning and memory impairment by normalizing glucose metabolism, restoring 5-HT levels, and inhibiting phosphodiesterase in the brain.
-
Animal Model:NIH mice (male)[1]
-
Dosage:3; 10; 30 mg/kg
-
Administration:i.g.
-
Result:Shortened immobility time in the tail suspension test.
Enhanced rotatory locomotor activities during forced swimming test.
Increased mortality induced by yohimbine and head-twitching number induced by 5-HTP.
Improved reserpine-induced hypothermia, akinesia, and eye ptosis.
-
Animal Model:C57BL/6 mice[1]
-
Dosage:10; 20 mg/kg
-
Administration:p.o.
-
Result:Inhibited hepatic steatosis and liver inflammation.
Improved energy expenditure.
Ameliorated acylcarnitine metabolism disorder via the SIRT3/LCAD signaling pathway.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2309-49-1
-
Appearance Solid
-
Molecular Weight 224.22
-
Formula C9H12N4O3
-
Color White to off-white
-
SMILES
O=C1C2=C(N(C)C(N2C)=O)N(C)C(N1C)=O
-
Synonyms
1,3,7,9-Tetramethyluric acid; Theacrine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
H2O : 25 mg/mL (111.50 mM; Need ultrasonic)
DMSO : 5 mg/mL (22.30 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sheng YY, et al. Theacrine From Camellia kucha and Its Health Beneficial Effects. Front Nutr. 2020 Dec 17;7:596823. [Content Brief]
[2]. Kihlman BA. 1,3,7,9-tetramethyluric acid--a chromosome-damaging agent occurring as a natural metabolite in certain caffeine-producing plants. Mutat Res. 1977;39(3-4):297-315. [Content Brief]
[3]. Zheng XQ, et al. Theacrine (1,3,7,9-tetramethyluric acid) synthesis in leaves of a Chinese tea, kucha (Camellia assamica var. kucha). Phytochemistry. 2002;60(2):129-134. [Content Brief]
[4]. Lints BS, et al. A caffeine and theacrine combination improves cognitive performance in tactical personnel under physically fatiguing conditions. J Int Soc Sports Nutr. 2025;22(1):2536146. [Content Brief]
[5]. Wang Y, et al. Theacrine, a purine alkaloid with anti-inflammatory and analgesic activities. Fitoterapia. 2010;81(6):627-631. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 4.4599 mL | 22.2995 mL | 44.5991 mL | 111.4976 mL |
| 5 mM | 0.8920 mL | 4.4599 mL | 8.9198 mL | 22.2995 mL | |
| 10 mM | 0.4460 mL | 2.2300 mL | 4.4599 mL | 11.1498 mL | |
| 15 mM | 0.2973 mL | 1.4866 mL | 2.9733 mL | 7.4332 mL | |
| 20 mM | 0.2230 mL | 1.1150 mL | 2.2300 mL | 5.5749 mL | |
| H2O | 25 mM | 0.1784 mL | 0.8920 mL | 1.7840 mL | 4.4599 mL |
| 30 mM | 0.1487 mL | 0.7433 mL | 1.4866 mL | 3.7166 mL | |
| 40 mM | 0.1115 mL | 0.5575 mL | 1.1150 mL | 2.7874 mL | |
| 50 mM | 0.0892 mL | 0.4460 mL | 0.8920 mL | 2.2300 mL | |
| 60 mM | 0.0743 mL | 0.3717 mL | 0.7433 mL | 1.8583 mL | |
| 80 mM | 0.0557 mL | 0.2787 mL | 0.5575 mL | 1.3937 mL | |
| 100 mM | 0.0446 mL | 0.2230 mL | 0.4460 mL | 1.1150 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz